Semavic Neхt (semaglutide) [Ozempic] 3 ml syringe pen 1 pc

Instructions for Semavic Neхt (semaglutide) [Ozempic] 3 ml syringe pen 1 pc

Semavic Neхt contains an active substance - semaglutide, which is an agonist of the glucagon-like peptide-1 (GLP-1R) receptor, obtained through chemical synthesis.

Semaglutide interacts with at least six of the eight key mechanisms of type 2 diabetes, improving the course and prognosis of the disease and improving the overall well-being of patients.
Clinically significant doses of semaglutide help lower blood glucose levels and weight loss. Semaglutide also has a positive effect on blood lipid profile, decreases systolic blood pressure, and reduces insulin resistance.
Semaglutide helps reduce overall body weight and body fat volume by reducing caloric intake. This mechanism includes a general decrease in appetite, an increased sense of satiety, a reduced sense of hunger, better control of food intake, and a reduction in nutritional cravings. Additionally, semaglutide reduces the tendency to eat foods high in fat.
Because semaglutide has a half-life of about one week, it can be given subcutaneously (n/a) once a week.

Pharmaceutical Characteristic Semavic Neхt:

The preparation is a transparent liquid that has no color or has a slight shade.
Therapeutic category: Hypoglycemic drug - analog of glucagon-like peptide-1 (GLP-1).

ATH Encoding: A10V106.

This drug is for you personally. Don’t give it to others, even if their symptoms are similar to yours, it can be dangerous.
If any adverse events occur, consult a specialist. This applies to all possible side effects, even if they are not listed in section 4 of the leaflet.

Indications for use Semavic Neхt

• Semavik Nechst is recommended for adults from 18 years old for comprehensive weight control. It is used in addition to a low-calorie diet and physical activity. Its use is justified for weight loss and maintenance in people with
• Obesity: Body mass index (BMI) ≥ 30 kg/m².
• Overweight: BMI ≥ 27 kg/m² but < 30 kg/m² in the presence of concomitant diseases associated with overweight.
• These disorders include
• Prediabetes or type 2 diabetes mellitus (DM2)
• Hypertension.
• Dyslipidemia.
• Obstructive sleep apnea.
• Cardiovascular diseases.

How to take and in what doses Semavic Neхt

Use the drug only when prescribed by your doctor. If you have questions or doubts, be sure to consult a doctor. The dosage and frequency of treatment will be determined by the doctor, taking into account your individual characteristics.

Adults:

• Initial dose: 0.5 mg once a week.
• Therapeutic dose: 2.4 mg once a week.
• Treatment begins with a minimum dose, which increases gradually over the first 16 weeks:
• Week 1-4: 0.5 mg once a week.
• Week 5-8: 1 mg once a week.
• Week 9-12: 1.5 mg once a week.
• Week 13-16: 2 mg once a week.
• Week 17 onwards: 2.4 mg once a week.